Approaches to interfere with NET formation or NET-associated products, such as DNases, antiproteases, supplementing surfactant protein D, targeting histones [66], or a combination thereof, could represent promising therapeutic strategies for CF lung disease and other chronic lung diseases associated with sustained neutrophilic inflammation [38, 40, 43]. Here, SFTPD is linked to chronic lung disease.